Abgeschlossene Studien

Studie	Studienleiter	Publikationen
Akute Hepatitis B	Prof. Dr. med. H. L. Tillmann
Akute Hepatitis C I	Prof. Dr. M. P. Manns
Akute Hepatitis C II	Prof. Dr. M. P. Manns	Economic evaluation of early monotherapy versus delayed monotherapy or combination therapy in patients with acute hepatitis C in Germany – Dintsios CM, Haverkamp A, Wiegand J, Gerlach T, Wedemeyer H, Pape G, Manns MP, Krauth C.: Eur J Gastroenterol Hepatol. 2009 Jun 22 Initial presentation of acute hepatitis C virus (HCV) infection among HIV-negative and HIV-positive individuals – experience from 2 large German networks on the study of acute HCV infection – Vogel M, Deterding K, Wiegand J, Grüner NH, Baumgarten A, Jung MC, Manns MP, Wedemeyer H, Rockstroh JK; German Hepatitis Group; Hep-Net: Clin Infect Dis. 2009 Jul 15;49(2):317-9 The German Hep-Net acute hepatitis C cohort: impact of viral and host factors on the initial presentation of acute hepatitis C virus infection – Deterding K, Wiegand J, Grüner N, Hahn A, Jäckel E, Jung MC, Buggisch P, Galle P, Berg T, Hinrichsen H, Potthoff A, Zeuzem S, Cornberg M, Manns M, Wedemeyer H.: Z Gastroenterol. 2009 Jun;47(6):531-40 Fate and function of hepatitis-C-virus-specific T-cells during peginterferon-alpha-2b therapy for acute hepatitis – Wiegand J, Cornberg M, Aslan N, Schlaphoff V, Sarrazin C, Kubitschke A, Buggisch P, Ciner A, Jaeckel E, Manns MP, Wedemeyer H.: Antivir Ther. 2007;12(3):303-16. Early monotherapy with pegylated interferon alpha-2b for acute hepatitis C infection: the HEP-NET acute-HCV-II study – Wiegand J, Buggisch P, Boecher W, Zeuzem S, Gelbmann CM, Berg T, Kauffmann W, Kallinowski B, Cornberg M, Jaeckel E, Wedemeyer H, Manns MP; German HEP-NET Acute HCV Study Group: Hepatology. 2006 Feb;43(2):250-6. Long-term follow-up after successful interferon therapy of acute hepatitis – Wiegand J, Jäckel E, Cornberg M, Hinrichsen H, Dietrich M, Kroeger J, Fritsch WP, Kubitschke A, Aslan N, Tillmann HL, Manns MP, Wedemeyer H.: Hepatology. 2004 Jul;40(1):98-107.
Akute Hepatitis III	Prof. Dr. M. P. Manns	Delayed versus immediate treatment for patients with acute hepatitis C: a randomised controlled non-inferiority trial.- Deterding K, Grüner N, Buggisch P, Wiegand J, Galle PR, Spengler U, Hinrichsen H, Berg T, Potthoff A, Malek N, Großhennig A, Koch A, Diepolder H, Lüth S, Feyeranbend S, Jung MC, Rogalska-Taranta M, Schlaphoff V, Cornberg M, Manns MP, Wedemeyer H, for the Hep-Net acute HCV-III Study-Group Lancet Infectious Diseases 2013 Jun;13(6):497-506. doi: 10.1016/S1473-3099(13)70059-8. Epub 2013 Mar 22.
Akute HCV-IV Studie	Prof. Dr. M. P. Manns	Ledipasvir plus sofosbuvir fixed-dose combination for 6 weeks in patients with acute hepatitis C virus genotype 1 monoinfection (HepNet Acute HCV IV): an open-label, single-arm, phase 2 study. Deterding K, Spinner CD, Schott E, Welzel TM, Gerken G, Klinker H, Spengler U, Wiegand J, Schulze Zur Wiesch J, Pathil A, Cornberg M, Umgelter A, Zöllner C, Zeuzem S, Papkalla A, Weber K, Hardtke S, von der Leyen H, Koch A, von Witzendorff D, Manns MP, Wedemeyer H; HepNet Acute HCV IV Study Group. Lancet Infect Dis. 2017 Feb;17(2):215-222. doi: 10.1016/S1473-3099(16)30408-X. Epub 2016 Oct 28.
ARFI	Prof. Dr. med. C. Sarrazin	Acoustic radiation force impulse imaging for evaluation of antiviral treatment response in chronic hepatitis C. - Forestier N, Gaus A, Herrmann E, Sarrazin C, Bojunga J, Poynard T, Albert J, Gerber L, Schneider MD, Dultz G, Zeuzem S, Friedrich-Rust M. - J Gastrointestin Liver Dis. 2012 Dec;21(4):367-73.
CHB-LTX Studie	PD Dr. med. Karsten Wursthorn Prof. Dr. med. Michael P. Manns
CIPPAD	Prof. Dr. med. T. Berg Priv. Doz. Dr. med. M. Schäfer	Schäfer et al., AASLD 2008
Genotyp 2/3 Studie	Prof. Dr. med. S. Zeuzem	Peginterferon-alpha-2a (40KD) and ribavirin for 16 or 24 weeks in patients with genotype 2 or 3 chronic hepatitis C. von Wagner M, Huber M, Berg T, Hinrichsen H, Rasenack J, Heintges T, Bergk A, Bernsmeier C, Häussinger D, Herrmann E, Zeuzem S.:Gastroenterology. 2005 Aug;129(2):522-7.
GIHALT (LTx)	Prof. Dr. med. Michael P. Manns
GT 2-3 Heidelberg	Frau Priv. Doz. Dr. med. B. Kallinowski
HBV/HCV Koinfektion	Prof. Dr. med. C. Trautwein, Prof. Dr. M. P. Manns	The HEP-NET B/C co-infection trial: A prospective multicenter study to investigate the efficacy of pegylated Interferon-α2b and ribavirin in patients with HBV/HCV co-infection - Andrej Potthoff, Heiner Wedemeyer, Wulf O. Böcher, Thomas Berg, Stefan Zeuzem, Joachim Arnold, Ulrich Spengler, Kurt Grüngreiff, Thomas Käser, Adam Kassai, Marcus Schuchmann, Alexandra Bergk, Nicole Forestier, Katja Deterding, Michael P. Manns, Christian Trautwein for the Hep-Net B/C Co-infection Study Group.. Journal of Hepatology 2008 , Volume 49 , Issue 5 , Pages 688 – 694. Late HBV relapse in patients co-infected with HBV and HCV after antiviral treatment with pegylated interferon-a2b (PEG-IFN-a2b) and ribavirin – Potthoff A, Berg T, Wedemeyer H for the HEP-NET B/C co-infection study group.. Scand J Gastroenterol. 2009;44(12):1487-90.
HCV Genotyp 1	Prof. Dr. med. T. Berg, Prof. Dr. med. Hopf
HCV-Longterm-PEG	Priv. Doz. Dr. med. A. Erhardt, Prof. Dr. med. D. Häussinger
Hepatische Fibrose	Prof. Dr. med. S. Zeuzem
HIDIT 1	Prof. Dr. med. M. P. Manns, Prof. Dr. med. H. Wedemeyer	Peginterferon plus adefovir versus either drug alone for hepatitis delta. Wedemeyer H, Yurdaydìn C, Dalekos GN, Erhardt A, Çakaloğlu Y, Değertekin H, Gürel S, Zeuzem S, Zachou K, Bozkaya H, Koch A, Bock T, Dienes HP, Manns MP; HIDIT Study Group. N Engl J Med. 2011 Jan 27;364(4):322-31. Late HDV RNA relapse after peginterferon alpha-based therapy of chronic hepatitis delta. Heidrich B, Yurdaydın C, Kabaçam G, Ratsch BA, Zachou K, Bremer B, Dalekos GN, Erhardt A, Tabak F, Yalcin K, Gürel S, Zeuzem S, Cornberg M, Bock CT, Manns MP, Wedemeyer H; HIDIT-1 Study Group. Hepatology. 2014 Jul;60(1):87-97 Renal function during treatment with adefovir plus peginterferon alfa-2a vs either drug alone in hepatitis B/D co-infection. Mederacke I, Yurdaydin C, Großhennig A, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Chatzikyrkou C, Bozkaya H, Dalekos GN, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. J Viral Hepat. 2012 Jun;19(6):387-95 Anti-HDV immunoglobulin M testing in hepatitis delta revisited: correlations with disease activity and response to pegylated interferon-α2a treatment. Mederacke I, Yurdaydin C, Dalekos GN, Bremer B, Erhardt A, Cakaloglu Y, Yalcin K, Gurel S, Zeuzem S, Zachou K, Bozkaya H, Dienes HP, Manns MP, Wedemeyer H; Hep-Net/International Delta Hepatitis Study Group. Antivir Ther. 2012;17(2):305-12 Hepatitis delta virus-specific cytokine responses in patients with chronic hepatitis delta before and during interferon alfa-treatment. Grabowski J, Yurdaydìn C, Zachou K, Buggisch P, Hofmann WP, Jaroszewicz J, Schlaphoff V, Manns MP, Cornberg M, Wedemeyer H; HIDIT-1 study group. Liver Int. 2011 Oct;31(9):1395-405
INDIV-2	Prof. Dr. C. Sarrazin	Improved responses to pegylated interferon alfa-2b and ribavirin by individualizing treatment for 24-72 weeks. Sarrazin C, Schwendy S, Möller B, Dikopoulos N, Buggisch P, Encke J, Teuber G, Goeser T, Thimme R, Klinker H, Boecher WO, Schulte-Frohlinde E, Prinzing R, Herrmann E, Zeuzem S, Berg T. Gastroenterology. 2011 Nov;141(5):1656-64.
OPTEX	Prof. Dr. med. M. P. Manns, Priv. Doz. Dr. med. M. Cornberg	Treatment Extension of Pegylated Interferon Alpha and Ribavirin Does Not Improve SVR in Patients with Genotypes 2/3 without Rapid Virological Response (OPTEX Trial): A Prospective, Randomized, Two-Arm, Multicentre Phase IV Clinical Trial. Heidrich B, Cordes HJ, Klinker H, Möller B, Naumann U, Rössle M, Kraus MR, Böker KH, Roggel C, Schuchmann M, Stoehr A, Trein A, Hardtke S, Gonnermann A, Koch A, Wedemeyer H, Manns MP, Cornberg M. PLoS One. 2015 Jun 9;10(6):e0128069. doi: 10.1371/
PIMODI	Prof. Dr. med. R. Zachoval
Prama	Prof. Dr. med. S. Zeuzem	Placebo-controlled trial of 400 mg amantadine combined with peginterferon alfa-2a and ribavirin for 48 weeks in chronic hepatitis C virus-1 infection - von Wagner M, Hofmann WP, Teuber G, Berg T, Goeser T, Spengler U, Hinrichsen H, Weidenbach H, Gerken G, Manns M, Buggisch P, Herrmann E, Zeuzem S. Hepatology. 2008 Nov;48(5):1404-11.
Redd 2/3	Prof. Dr. med. M. P. Manns, Prof. Dr. med. H. Wedemeyer	Manns et al., EASL 2009 Manns et al., AASLD 2009
TRELA Relapse	Dr. P. Buggisch	Buggisch et al., EASL 2009
PADD-ON	Prof. Dr. med. P. Galle	Prospective Randomized Open-label Trial Protocol Investigating the Addition of Pegylated Interferon-alpha to an Ongoing Nucleos(t)ide Treatment Regimen of HBeAg Negative Chronic Hepatitis B Patients (PADD-ON). Sprinzl MF, Grambihler A, Kittner JM, Wachtlin D, Ruckes C, et al. (2015) J Clin Trials 5: 226. doi:10.4172/2167-0870.1000226